Iceland· IS-EU/1/15/1014/001-004
Opdivo
A nivolumab product containing nivolumabum inn, registered in Iceland by Bristol-Myers Squibb Pharma EEIG*. The same ATC class is registered in 13 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Nivolumab is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FF01 (nivolumab), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 8 of them publish a price we can compare per daily dose
Nivolumab · ATC L01FF01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Nivolumabum INN
- Manufacturer
- Bristol-Myers Squibb Pharma EEIG*
- Country
- Iceland (IS)
- ATC code
- L01FF01
- ATC class
- Nivolumab
- Defined daily dose
- 17.1 mg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 3
3 priced- ean47995424 ml x1 hglISK 539151
- ean5393854 ml x1 hglISK 81102
- ean57924010 ml x1 hglISK 196770
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
22 interactions on record for nivolumab.
Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Nivolumab · interactions on record
22 records
- 3 severe
- 19 moderate
Most severe, free to view
- ThalidomideL04AX02severe
- LenalidomideL04AX04severe
- PomalidomideL04AX06severe
- PrednisoloneA07EA01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Nivolumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandNivolumab BmsBristol-Myers Squibb Pharma EEIG
- CzechiaOPDIVOBristol-Myers Squibb Pharma EEIG, Dublin
- BelgiumOpdivo 10 mg/mlBristol-Myers Squibb Pharma
- NorwayOpdivoBristol-Myers Squibb Pharma EEIG
- PolandOpdivoBristol-Myers Squibb Pharma EEIG
- SwedenOPDIVO 10 mg/ml Koncentrat till infusionsvätska, lösningBristol-Myers Squibb Pharma EEIG
- SwitzerlandOpdivo 120 mg/12 ml, Konzentrat zur Herstellung einer InfusionslösungBristol-Myers Squibb SA
- IrelandOPDIVO 10 mg/mL concentrate for solution for infusionBristol-Myers Squibb Pharma EEIG
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Opdivo
- Norway · Opdivo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/3fa5e0d0-4303-48bd-8ab8-b0eca04d8087 GET /v1/drugs/3fa5e0d0-4303-48bd-8ab8-b0eca04d8087?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Innrennslisþykkni, lausn",
"source": "lyfjastofnun",
"atc_raw": "L01FF01",
"marketed": true,
"strength": "10 mg/ml",
"ma_number": "EU/1/15/1014/001-004",
"substance": "Nivolumabum INN",
"other_info": "Markaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
"legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
"ma_issued_serial": "42174"
}See everything about nivolumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.